Program
hepalatide
Also written as “Hepalatide”, “Hepalatide 2.1mg” and “Hepalatide 4.2mg”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis D, Chronic · Hepatitis D · Diabetes Mellitus, Type 2, led by Shanghai HEP Pharmaceutical.
Furthest: phase 3, since Dec 16, 20258 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai HEP Pharmaceutical | 81 open or running | phase 3since Dec 16, 2025 | Sep 16, 2015 | Jun 2028phase 3 · NCT07309380 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2015First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT02612506 · 48 enrolled · China
- Jan 15, 2017Phase 1 study in Hepatitis B, ChronicNCT03023787 · 35 enrolled · China
- Jun 9, 2020Phase 2 study in Hepatitis B, ChronicNCT04426968 · 96 enrolled · China
- Dec 3, 2020Phase 2 study in Type 2 Diabetes PatientsNCT04662164
- Feb 3, 2022Phase 2 study in Hepatitis B, ChronicNCT05244057 · 8 enrolled · China
- Feb 17, 2023Phase 2 study in Hepatitis D, ChronicNCT05827146 · 23 enrolled · China, Mongolia
- Jul 10, 2024Phase 2 study in Hepatitis DNCT06505928 · 90 enrolled · Mongolia
- Dec 16, 2025Phase 3 study in Hepatitis D, ChronicPhase 3 reachedNCT07309380 · 150 planned · China
Ahead
- Jun 2028Primary completion: phase 3 study in Hepatitis D, ChronicNCT07309380
TargetBeta
SLC10A1 →read by rule
“Bile acid transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC10A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bulevirtiderule | Gilead Sciences | phase 3 | 5 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07309380Hepatitis D, Chronic · China | 3 | Not yet recruiting | Jun 2028 | 150 |
| NCT06505928Hepatitis D · Mongolia | 2 | Completed | May 1, 2026 | 90 |
| NCT05827146Hepatitis D, Chronic · China, Mongolia | 2 | Completed | Jan 30, 2024 | 23 |
| NCT05244057Hepatitis B, Chronic · China | 2 | Completed | Jun 24, 2024 | 8 |
| NCT04662164Type 2 Diabetes Patients | 2 | Withdrawn | Dec 2025 | 0 |
| NCT04426968Hepatitis B, Chronic · China | 2 | Completed | Nov 1, 2023 | 96 |
| NCT03023787Hepatitis B, Chronic · China | 1 | Completed | Dec 2016 | 35 |
| NCT02612506Hepatitis B, Chronic · China | 1 | Completed | Aug 2016 | 48 |
How it is read
Names in the registry
- “Hepalatide”, 4 entries
- “hepalatide”, 2 entries
- “Hepalatide 2.1mg”, 2 entries
- “Hepalatide 4.2mg”, 1 entry
- “Hepalatide 6.3mg”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
- Hepatitis D, Chronic, 2 studies
- Hepatitis D, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.